Literature DB >> 15787675

alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.

K Hücking1, Z Kostic, C Pox, R Ritzel, J J Holst, W Schmiegel, M A Nauck.   

Abstract

AIM: Acarbose is able to enhance GLP-1 release and delay gastric emptying in normal subjects. The effect of alpha-glucosidase inhibition on GLP-1 has been less evident in Type 2 diabetic patients. The aim of this study was to investigate the possible influence of acarbose on GLP-1 release and gastric emptying in Type 2 diabetic patients after a mixed test meal. PATIENTS AND METHODS: Ten Type 2 diabetic patients were tested with 100 mg acarbose or placebo served with a mixed meal that was labelled with 100 mg 13C-octanoic acid. Plasma concentrations of glucose, insulin, C-peptide, glucagon, GLP-1 and GIP were determined over 6 h. Gastric emptying was measured by determining breath 13CO2 using infrared absorptiometry. Statistics repeated-measures anova.
RESULTS: Gastric emptying rates (t1/2: 162 +/- 45 vs. 163 +/- 62 min, P = 0.65) and plasma concentrations (increasing from approximately 12 to approximately 25 pmol/l, P = 0.37) and integrated responses of GLP-1 (P = 0.37) were not changed significantly by acarbose treatment. Postprandial plasma glucose concentrations (P < 0.0001) and their integrated responses were lowered by acarbose (by 64%; P = 0.016). The plasma concentrations of insulin and C-peptide were reduced (P = 0.007 and 0.057, respectively) by acarbose, while glucagon was not changed (P = 0.96). GIP plasma concentrations (increasing with placebo from approximately 10 to approximately 85 pmol/l and with acarbose to approximately 55 pmol/l (P < 0.0001) and their integrated responses were significantly lowered (by 43%) by acarbose (P = 0.021). After 2 weeks of acarbose treatment (50 mg t.i.d. for the first and 100 mg t.i.d. for the second week, n = 6), similar results were found.
CONCLUSIONS: In hyperglycaemic Type 2 diabetic patients, ingestion of acarbose with a mixed test meal failed to enhance GLP-1 release and did not influence gastric emptying.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15787675     DOI: 10.1111/j.1464-5491.2005.01451.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  20 in total

Review 1.  Upper gastrointestinal function and glycemic control in diabetes mellitus.

Authors:  Reawika Chaikomin; Christopher K Rayner; Karen-L Jones; Michael Horowitz
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

Review 2.  Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control.

Authors:  Ryan J Jalleh; Karen L Jones; Christopher K Rayner; Chinmay S Marathe; Tongzhi Wu; Michael Horowitz
Journal:  Diabetologia       Date:  2022-10-04       Impact factor: 10.460

3.  Targeting the Enteroendocrine System for Treatment of Obesity.

Authors:  Emily L Miedzybrodzka; Fiona M Gribble; Frank Reimann
Journal:  Handb Exp Pharmacol       Date:  2022

4.  Role of intestinal peptides and the autonomic nervous system in postprandial hypotension in patients with multiple system atrophy.

Authors:  Takeshi Fukushima; Masato Asahina; Yoshikatsu Fujinuma; Yoshitaka Yamanaka; Akira Katagiri; Masahiro Mori; Satoshi Kuwabara
Journal:  J Neurol       Date:  2012-09-15       Impact factor: 4.849

Review 5.  New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.

Authors:  Angela M Abbatecola; Stefania Maggi; Giuseppe Paolisso
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 6.  Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated?

Authors:  Guillaume Charpentier; Jean-Pierre Riveline; Dured Dardari; Michel Varroud-Vial
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial.

Authors:  Hidetaka Yokoh; Kazuki Kobayashi; Yasunori Sato; Minoru Takemoto; Daigaku Uchida; Azuma Kanatsuka; Nobuichi Kuribayashi; Takashi Terano; Naotake Hashimoto; Kenichi Sakurai; Hideki Hanaoka; Ko Ishikawa; Shunichiro Onishi; Koutaro Yokote
Journal:  J Diabetes Investig       Date:  2014-09-24       Impact factor: 4.232

8.  Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study.

Authors:  Hiroaki Ueno; Wakaba Tsuchimochi; Hong-Wei Wang; Eiichiro Yamashita; Chikako Tsubouchi; Kazuhiro Nagamine; Hideyuki Sakoda; Masamitsu Nakazato
Journal:  Diabetes Ther       Date:  2015-06-09       Impact factor: 2.945

9.  Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance.

Authors:  Kiyomi Masuda; Kazutaka Aoki; Yasuo Terauchi
Journal:  J Diabetes Investig       Date:  2011-11-30       Impact factor: 4.232

10.  Management of type 2 diabetes mellitus in older adults.

Authors:  Kyung Soo Kim; Soo Kyung Kim; Kyung Mi Sung; Yong Wook Cho; Seok Won Park
Journal:  Diabetes Metab J       Date:  2012-10-18       Impact factor: 5.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.